Ítem
Acceso Abierto

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population

Mostrar el registro sencillo de la publicación
dc.creatorRodríguez, Francisco Josespa
dc.creatorRios, Hernan Andresspa
dc.creatorAguilar, María Camilaspa
dc.creatorRosenstiehl, Shirley Margaritaspa
dc.creatorGelvez, Nancyspa
dc.creatorLopez, Greizyspa
dc.creatorTamayo, Martha Lspa
dc.date.accessioned2020-05-26T00:01:25Z
dc.date.available2020-05-26T00:01:25Z
dc.date.created2019spa
dc.description.abstractAge-related macular degeneration (AMD) is the leading cause of visual impairment in patients over 55 years. Currently, the most common therapies for neovascular AMD (nAMD) are intravitreal antiangiogenics. Studies suggest that genetic factors influence on antiangiogenics therapy outcomes. The purpose of this work was to establish the association between complement factor H (CFH) (Y402H), age-related maculopathy susceptibility 2 (ARMS2) (A69S), and high-temperature requirement factor A1 (HTRA1) (rs11200638) polymorphisms and the response to treatment with ranibizumab in patients with nAMD. METHODS: A cross-sectional study with 61 eyes with nAMD treated with ranibizumab was performed. Association between polymorphisms from CFH, ARMS2, and HTRA1 with the response to treatment was established. RESULTS: The mean age of patients was 76.6 (51-91) years. Only 37.7% of patients had a functional response and 26.2% had an anatomic response. TT polymorphism Y402H from CFH gene was associated with an increased likelihood of functional response to treatment. Otherwise, there was not a statistically significant association between anatomic and functional response to gene polymorphisms rs11200638 from HTRA1 and rs10490924 from ARMS 2. CONCLUSIONS: This study suggests that the response to intravitreal antiangiogenic therapy with ranibizumab was not associated to main polymorphisms from genes HTRA1 and ARMS2. However, it was found that the response to treatment differed according to CFH genotype, suggesting that further investigations are needed to establish if patients with the CC and TC genotype may need to be monitored more closely for disease recurrence than the TT genotype. © 2019 Taiwan J Ophthalmoleng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.4103/tjo.tjo_72_19
dc.identifier.issn22115056
dc.identifier.issn22115072
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23364
dc.language.isoengspa
dc.publisherWolters Kluwer Medknow Publicationsspa
dc.relation.citationEndPage248
dc.relation.citationIssueNo. 4
dc.relation.citationStartPage243
dc.relation.citationTitleTaiwan Journal of Ophthalmology
dc.relation.citationVolumeVol. 9
dc.relation.ispartofTaiwan Journal of Ophthalmology, ISSN:22115056, 22115072, Vol.9, No.4 (2019); pp. 243-248spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85076821403&doi=10.4103%2ftjo.tjo_72_19&partnerID=40&md5=29a50709a6b9063a5aa2a0a40520a4f0spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAngiogenesis inhibitorsspa
dc.subject.keywordHispanic Americansspa
dc.subject.keywordMacular degenerationspa
dc.subject.keywordPolymorphismspa
dc.titleGenetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic populationspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
TaiwanJOphthalmol94243-559071_153147.pdf
Tamaño:
519.38 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos